KR20040097716A - Health food comprising the extract of Actinidia arguta for preventing and improving baldness disorders and seborrheic skin disorders - Google Patents
Health food comprising the extract of Actinidia arguta for preventing and improving baldness disorders and seborrheic skin disorders Download PDFInfo
- Publication number
- KR20040097716A KR20040097716A KR1020030030089A KR20030030089A KR20040097716A KR 20040097716 A KR20040097716 A KR 20040097716A KR 1020030030089 A KR1020030030089 A KR 1020030030089A KR 20030030089 A KR20030030089 A KR 20030030089A KR 20040097716 A KR20040097716 A KR 20040097716A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- hair
- soluble
- fraction
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 85
- 201000004384 Alopecia Diseases 0.000 title claims description 48
- 230000003676 hair loss Effects 0.000 title claims description 22
- 208000017520 skin disease Diseases 0.000 title claims description 10
- 244000298800 Actinidia arguta Species 0.000 title abstract description 8
- 235000016416 Actinidia arguta Nutrition 0.000 title abstract description 8
- 235000013402 health food Nutrition 0.000 title abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 239000012454 non-polar solvent Substances 0.000 claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000287 crude extract Substances 0.000 claims abstract description 16
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 230000003779 hair growth Effects 0.000 claims description 24
- 208000024963 hair loss Diseases 0.000 claims description 21
- 230000036541 health Effects 0.000 claims description 20
- 235000013361 beverage Nutrition 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 17
- 235000013376 functional food Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 235000015872 dietary supplement Nutrition 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 10
- 230000006872 improvement Effects 0.000 claims description 9
- 239000012046 mixed solvent Substances 0.000 claims description 9
- 230000003658 preventing hair loss Effects 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 241000219068 Actinidia Species 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 6
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 4
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 4
- 240000001851 Artemisia dracunculus Species 0.000 claims description 4
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 4
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 4
- 239000001138 artemisia absinthium Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 235000005985 organic acids Nutrition 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 1
- 210000004209 hair Anatomy 0.000 abstract description 30
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 abstract description 21
- 229960003473 androstanolone Drugs 0.000 abstract description 20
- 230000015572 biosynthetic process Effects 0.000 abstract description 12
- 238000000605 extraction Methods 0.000 abstract description 10
- 239000002904 solvent Substances 0.000 abstract description 9
- 210000002374 sebum Anatomy 0.000 abstract description 6
- 230000028327 secretion Effects 0.000 abstract description 6
- 235000013373 food additive Nutrition 0.000 abstract description 2
- 239000002778 food additive Substances 0.000 abstract description 2
- 201000004624 Dermatitis Diseases 0.000 abstract 3
- 230000035617 depilation Effects 0.000 abstract 3
- 229940093499 ethyl acetate Drugs 0.000 abstract 1
- 235000019439 ethyl acetate Nutrition 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 231100000360 alopecia Toxicity 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 239000003814 drug Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 210000004761 scalp Anatomy 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 206010068168 androgenetic alopecia Diseases 0.000 description 9
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 9
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 9
- 239000002038 ethyl acetate fraction Substances 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 9
- 239000005556 hormone Substances 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 201000002996 androgenic alopecia Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 208000004631 alopecia areata Diseases 0.000 description 7
- 210000003128 head Anatomy 0.000 description 7
- 230000003752 improving hair Effects 0.000 description 7
- 102000011782 Keratins Human genes 0.000 description 6
- 108010076876 Keratins Proteins 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 241000255789 Bombyx mori Species 0.000 description 5
- 239000012223 aqueous fraction Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002036 chloroform fraction Substances 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- 239000012676 herbal extract Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 108091008039 hormone receptors Proteins 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 229960003632 minoxidil Drugs 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 102000014654 Aromatase Human genes 0.000 description 3
- 108010078554 Aromatase Proteins 0.000 description 3
- 208000001840 Dandruff Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000003797 telogen phase Effects 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 240000007049 Juglans regia Species 0.000 description 2
- 235000009496 Juglans regia Nutrition 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 241000382353 Pupa Species 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 244000000231 Sesamum indicum Species 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000001522 artemisia absinthium l. herb extract Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 230000003659 hair regrowth Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000004918 root sheath Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 235000020234 walnut Nutrition 0.000 description 2
- 229940119569 wormwood extract Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 150000000520 4-azasteroids Chemical group 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 240000007822 Actinidia kolomikta Species 0.000 description 1
- 240000006274 Actinidia polygama Species 0.000 description 1
- 241000219066 Actinidiaceae Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 244000061408 Eugenia caryophyllata Species 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 241000388430 Tara Species 0.000 description 1
- 241000120020 Tela Species 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000007215 black sesame Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004069 plant analysis Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 생약추출물을 함유한 건강기능식품에 관한 것으로, 보다 상세하게는 다래(Actinidia arguta) 조추출물, 비극성용매 가용추출물 또는 정제 분획물을 함유하는 탈모증상 및 지루성 피부 증상의 예방 및 개선 효과를 지닌 기능성 식품에 관한 것이다.The present invention relates to a health functional food containing herbal extracts, and more particularly, has the effect of preventing and improving hair loss symptoms and seborrheic skin symptoms containing Actinidia arguta crude extracts, nonpolar solvent soluble extracts or purified fractions. It relates to a functional food.
탈모증은 남녀 모두에게서 흔히 볼 수 있는 증상이며 이로 인해서 많은 사람들이 생활에 지장을 받고 있고 탈모증을 치료하거나 외모를 개선하기 위해서 상당한 사회적 비용이 지출되고 있다. 정상적인 모발의 성장은 성장기(anagen), 퇴축기(catagen) 그리고 휴식기(telogen)의 주기에 따라서 이루어진다. 동물의 털이나 인체의 다른 부위의 모발에 비해 인간 머리카락은 상대적으로 긴 성장주기를 가진다(성장기, 2-5년; 퇴축기, 수일-수주; 휴식기, 3달). 모발의 성장주기를 조절하는 과정에는 여러 요인이 관여하는 것으로 알려져 있으나 아직 정확한 작용 기작은 정확히 알려져 있다.Alopecia is a common symptom in both men and women, and many people are hampered by their lives, and significant social costs are being spent to treat alopecia and improve their appearance. Normal hair growth follows the cycles of anagen, catagen and telogen. Human hair has a relatively long growth cycle compared to animal hair or other parts of the human body (growth, 2-5 years; degenerate, days-weeks; rest, 3 months). Many factors are involved in controlling the hair growth cycle, but the exact mechanism of action is still known.
탈모증은 크게 두 종류가 있다. 첫째는 남성형 탈모증(male pattern baldness), 장년형 탈모증(alopecia seniles) 또는 남성호르몬성 탈모증 (androgenic alopecia)이라고 불리는 것으로 중년 남성에서 흔히 볼 수 있으며 전두부와 두정부에서 시작되고, 둘째로는 원형 탈모증(alopecia areata)이라고 불리는 것으로 원형 내지는 타원형의 비교적 경계가 명확한 탈모를 보이며 청소년기에 발생할 수 있는 탈모증이 있다. 탈모증은 남성에만 있는 질병이 아니고 여성에서도 발생하며, 탈모증의 대부분은 남성형 탈모증으로서 남녀에 상관없이 발생한다. 원형 탈모증 역시 남녀 모두에게 발생하나 여성이 남성에 비하여 발생 빈도가 낮다. (M. Inaba 등, Androgenetic Alopecia, Springer-Berlag, Tokyo, Japan, 1996).There are two main types of alopecia. The first is called male pattern baldness, alopecia seniles, or androgenetic alopecia. It is common in middle-aged men and begins in the frontal head and head government. It is called alopecia areata, and it has a relatively borderless hair loss of round or oval shape and alopecia that can occur in adolescence. Alopecia is not only a disease in men but also occurs in women, and most of the alopecia is masculine alopecia, regardless of gender. Alopecia areata also occurs in both men and women, but women are less frequent than men. (M. Inaba et al., Androgenetic Alopecia, Springer-Berlag, Tokyo, Japan, 1996).
일반적으로 사람의 두발이 탈모되는 원인은 유전적 요인, 노화의 진행, 약물 복용, 방사선 치료, 및 중병 후 스트레스 등을 들 수 있다. 생화학적 및 생리학적 관점에서 탈모 현상은 남성호르몬의 과다 활동, 두피 혈액순환의 문제 및 모발대사에 필수적인 영양소의 결핍의 세가지 주요 원인에 의한 것이라고 알려져 있다. 상기 세가지 요인들이 단독으로도 탈모를 유발할 수 있지만, 탈모요인들이 복합되어 상승작용을 일으키게 되면 탈모증이 가속화되고 증상이 심해지게 된다. 특히, 유전적 요인 또는 후천적 특수조건으로 인하여 남성호르몬의 생성, 변화, 인식 및 신호전달 과정이 과도하게 작동하여 모낭 조직이 조기 노화되는 경향을 갖게 된다면 그렇지 않은 일반인 보다 조기에 대머리가 될 확률이 높다. 또한 유전적 요인, 노화, 서구적 고지방 식생활 및 기타 외부적 요인으로 인하여 두피의 긴장도가 쉽게 높아지거나 동맥경화증 등의 증상이 있는 경우 혈액순환 장애가 쉽게 일어나므로 원활한 모발 대사에 장애가 생긴다.In general, the causes of human hair loss include genetic factors, the progress of aging, drug use, radiation therapy, and post-stress stress. From a biochemical and physiological point of view, hair loss is known to be caused by three major causes of hyperactivity of male hormones, problems with scalp blood circulation, and a lack of nutrients essential for hair metabolism. Although these three factors alone can cause hair loss, when hair loss factors are combined to cause synergy, hair loss is accelerated and symptoms become worse. In particular, if genetic factors or acquired special conditions cause the production and alteration of male hormones, recognition, and signaling overworking, hair follicle tissues tend to age prematurely, which is likely to cause premature baldness. . In addition, due to genetic factors, aging, Western high-fat diet and other external factors, the tension of the scalp is easily increased, or if there are symptoms such as arteriosclerosis, blood circulation disorders occur easily, and thus, there is a problem in smooth hair metabolism.
이 중, 남성형 탈모증의 주요 원인은 남성호르몬(androgen)과 스테로이드 호르몬이 관련되어 있는 것으로 알려져 있다(J. Shapiro 등, Therapeutic agents,Dermatol. Clin.,16(2), pp341-356, 1998). 또한 남성호르몬 수용체 분포의 차이도 탈모증의 원인이 될 수 있다고 알려져 있다. 남성호르몬 수용체 (androgen receptor protein)는 두모의 외모근초(outer root sheath)와 모유두 (dermal papilla)의 결합조직형성세포(섬유아세포, fibroblast)에 분포되어 있으며, 탈모증을 일으킨 남성이나 여성에서는 탈모가 나타난 전두부와 두정부에서 30 % 이상 분포량이 많았다. 이는, 남성호르몬 수용체와의 결합에 의해 유발되는 세포핵으로의 신호 전달 과정이 모유두와 모낭세포(follicular cell)에 영향을 미쳐서, 성장기의 모근을 퇴축기, 또는 휴식기 상태로 유도할 수 있다는 것이다.Among them, the main cause of androgenetic alopecia is known to be related to androgen and steroid hormones (J. Shapiro et al ., Therapeutic agents, Dermatol. Clin ., 16 (2) , pp341-356, 1998). It is also known that differences in the distribution of male hormone receptors can also cause alopecia. The androgen receptor protein is distributed in the connective tissue forming cells (fibroblasts) of the outer root sheath and dermal papilla of the hair, and hair loss occurs in men and women who have caused alopecia. More than 30% were distributed in the frontal head and head government. This means that the signal transduction process to the cell nucleus caused by the binding of the male hormone receptor may affect the dermal papilla and follicular cells, leading to the hair root of the growing phase in the retracted or resting state.
남성형 탈모증에는 남성호르몬과 그 수용체 뿐 아니라, 여기에 효소작용이 영향을 미친다. 현재 탈모와 관련되는 스테로이드 호르몬 대사효소로 문제가 되는 것은 환원효소(5-α-reductase)와 아로마타제(aromatase)이다. 먼저, 환원효소는 테스토스테론을 남성호르몬 (androgen)의 일종으로 효력이 강화된 형태인 디히드로테스토스테론(DHT)으로 환원시킨다. 탈모와 관련이 있는 기관으로는 피지선 (sebaceous gland), 표피와 모낭의 각화세포(keratinocytes), 진피유두세포(dermal papilla cell), 한선(sweat gland), 모근초(root sheath of the scalp hair follicle) 등이 있는데, 특히 피지선이 주목되고 있다. 대머리가 있는 부위의 조직은 보통의 머리가 있는 부위의 조직보다 환원효소의 활성도가 높다고 보고되어 있다. 아로마타제는 남성호르몬(androgen)을 에스트라디올 등의 여성호르몬으로 전환시키는 탈모증이 있는 사람의 전두부에서는 그 활성이 낮다고 알려져 있다. 이러한 사실을 고려할 때 남성형 탈모증의 주된 원인은 남성호르몬, 남성호르몬을 변형시키는 효소, 그리고 남성호르몬 수용체 간의 상호관계에 있다고 할 수 있다.Androgenetic alopecia affects not only male hormones and their receptors, but also enzyme activity. At present, the problem with steroid hormone metabolism related to hair loss is the reductase (5-α-reductase) and aromatase (aromatase). First, the reductase reduces testosterone to dihydrotestosterone (DHT), an enhanced form of male hormone (androgen). Hair loss-related organs include sebaceous gland, epidermis and keratinocytes, dermal papilla cells, sweat gland, and root sheath of the scalp hair follicle. Etc., in particular, the sebaceous gland is attracting attention. Tissues in bald areas are reported to have higher reductase activity than those in normal head areas. Aromatase is known to have low activity in the frontal head of alopecia, which converts male hormone (androgen) to female hormones such as estradiol. Considering this fact, the main cause of androgenetic alopecia may be due to the interrelationship between male hormones, enzymes that modify male hormones, and male hormone receptors.
원형 탈모증은 원형 또는 타원형으로 탈모의 경계가 명확하며, 단발 또는 다발이 될 수도 있고, 심하면 두발 전부 혹은 눈썹까지 빠지는 경우도 있다(범발성 탈모증). 단발성인 것들은 특별한 치료 없이 치유되기도 하지만 범위가 넓은 경우는 재발할 수 있다. 최근의 세포생물학적 연구에 의하면 원형탈모증이 일종의 자가면역질환인 것으로 밝혀지고 있다. 즉, 모포에 손상을 줄 수 있는 임파구(CD4+)가 모포의 주변에 집결하여 있고 주된 표적은 멜라닌세포(melanocyte), 각화세포 (keratinocyte), 모유두(dermal papilla), 그리고 혈관내피세포(vascular endothe lium)로 알려져 있다.Alopecia areata is a round or oval with a clear border of hair loss, may be a single or multiple bundles, and in some cases, both the hair and even the eyebrows (external alopecia). Short-lived ones may heal without special treatment, but may recur in a wide range. Recent cell biology studies have shown that alopecia areata is a type of autoimmune disease. In other words, lymphocytes (CD4 +) that can damage the follicles are concentrated around the follicles and the main targets are melanocytes, keratinocytes, dermal papilla, and vascular endothe lium. Is known as
남성형 탈모증이나 원형 탈모증 이외에, 각종 항암제를 투여하였을 때 탈모 현상이 발생한다. 항암제는 사람과 동물에 투여하였을 때 분열하는 조직에 가장 먼저 작용하는데 암조직은 물론 조혈 장기, 위장관 내피세포군, 그리고 피부의 피지선과 모낭세포에도 작용하게 되므로 부작용으로 탈모가 유발된다.In addition to androgenetic alopecia and alopecia areata, hair loss occurs when various anticancer drugs are administered. When administered to humans and animals, anticancer drugs are the first to act on dividing tissues and cause hair loss as a side effect because they act on cancer tissues, hematopoietic organs, gastrointestinal endothelial cell groups, and sebaceous gland and hair follicle cells of the skin.
남성형 탈모증의 치료를 위해서 5-알파-환원효소 저해제 (5-alpha-reductase inhibitor)가 경구용으로 사용되고 있다. 시판되는 약물로는 피나스테라이드 (Finasteride)가 있는데, 이것은 4-아자스테로이드 구조를 갖는 것으로 테스토스테론이 보다 역가가 강한 DHT로 환원되지 못하게 하여 남성호르몬의 역가를 저하시킨다. 하지만 이 약은 투약을 중단하면 재발한다는 것과, 가임 여성이나 임산부는 사용할 수 없고 장기 투여는 남성의 성기능을 약화시키는 부작용이 있다. 다른 치료제로서는 남성호르몬 수용체 마비제가 있는데, 이것은 여성에게만 사용될 수 있다.이 밖에 사이프로테론 아세테이트(cyproterone acetate), 스피로노락톤 (spironola ctone), 에스트로겐 등을 탈모증에 치료 효과가 있다고 알려져 있다 (J. Shapiro 등, Hair regrowth, Therapeutic agents,Dermatol. Clin. 16(2), 1998). 남성형 탈모증의 다른 치료제로서는 세포분열 촉진제, 혈관 확장제, 모세혈관 발생 촉진제, 면역 억제제, cAMP 조절제, 상피세포 생장인자(EGF), 세포발생과정 조절제 등 많은 생물학적 반응 조절제가 문헌에 열거되어 있으며, 이중 시판되는 것으로는 미녹시딜 (Minoxidil)이 있다. 미녹시딜은 원래 혈관 확장제로서 고혈압 치료에 사용되던 것으로 탈모 부위에 적용하여 유효성을 나타내기는 하지만, 사용을 중단하면 재발하며 혈압을 떨어뜨릴 수 있다는 부작용이 있다.5-alpha-reductase inhibitors are used for oral treatment for androgenetic alopecia. Commercially available drugs include finasteride, which has a 4-azasteroid structure, which prevents testosterone from being reduced to more potent DHT, thereby lowering the titer of male hormones. However, the drug relapses when it is discontinued, and cannot be used by women of childbearing potential or pregnant women. Other therapeutic agents include male hormone receptor paralysis, which can only be used in women. Cyproterone acetate, spironola ctone, and estrogen are known to be effective in treating alopecia (J. Shapiro et al. , Hair regrowth, Therapeutic agents, Dermatol. Clin. 16 (2) , 1998). Other therapeutic agents for androgenetic alopecia include many biological response modifiers, such as cell division promoters, vasodilators, capillary development promoters, immunosuppressants, cAMP modulators, epidermal growth factor (EGF), and cytogenicity modulators. There is a minoxidil (Minoxidil). Minoxidil was originally used to treat hypertension as a vasodilator and has been shown to be effective when applied to the hair loss site. However, minoxidil has the side effect of recurring and lowering blood pressure when stopped.
원형 탈모증의 치료에는 면역 조절제가 사용되는데 대표적인 약은 부신피질호르몬제로서 임파구에 작용하여 면역 억제 효과를 목적으로 사용되어 피하주사 및 연고로 사용되지만, 재발 및 부작용의 문제점이 있어 장기간 사용이 어렵다.In the treatment of alopecia areata, an immunomodulatory agent is used. Representative drugs are corticosteroids, which act on lymphocytes and are used for the purpose of immunosuppressive effects and are used as subcutaneous injections and ointments.
이상에서 살펴 본 바와 같이 남성형 탈모증이나 원형 탈모증, 어느 경우에나 이렇다 할 치료제가 없을 뿐 아니라, 사용되는 약제들도 부작용이 심하다든가 유효성이 낮다든가 하는 문제가 있음을 알 수 있다.As discussed above, male alopecia and alopecia areata, as well as there is no treatment in any case, the drugs used can be seen that there are problems such as severe side effects or low effectiveness.
생약성분의 추출물을 이용하여 두피에 바르거나 복용함으로써 발모를 촉진시키려는 시도 또한 많이 있었는데, 난초과 식물의 추출물을 이용하는 경우(대한민국특허 제0157667호), 웅지와 만형자를 이용하는 경우(대한민국 특허 제0161338호), 만병초 엑기스를 유효성분으로 사용하는 경우(한국특허공개 제91-106호), 소나무잎 추출물을 이용한 발모촉진제(한국특허공개 제96-40346호), 누에 등을 이용한 발모촉진제(한국특허공개 제 90-2757호), 오갈피 뿌리, 단너삼 뿌리, 적하수오 뿌리, 부채마, 및 메밀을 유효성분으로 하는 발모 육모제(한국공개 특2000-24499), 반하, 정향, 복분자, 산초, 만형자, 단삼 및 백자인을 이용하는 경우(대한민국 특허 제259037), 원잠아, 잠종, 잠태, 잠사, 및 번데기를 약 200℃에서 15분 정도 가열하여 얻은 기름을 사용하는 경우 (한국공개특허 제90-2757호), 인삼, 황기, 당귀, 하수오, 호도, 복분자, 생지황, 보골지, 송채, 단삼, 홍화, 여정실 혼합 추출물을 사용하는 경우(한국공개특허 제90-13934호), 원잠아(누에나방), 잠종(누에씨), 번데기(누에), 검은깨, 다시마, 참깨, 및 호두알을 고압 고온 추출하여 사용하는 경우(한국공개특허 제90-5952호), 녹두분, 대두분, 흑미분, 들깨분, 참깨분, 호두분, 김분, 홍합분, 굴분, 멸치분, 미역분, 다시마분, 효모농축액 또는 이의 건조분을 혼합 사용하는 경우(대한민국 특허 제0260673호), 사상자, 솔잎, 및 원잠아를 사용하는 경우(한국공개특허 제90-002757호), 구기자 열매, 뿌리, 가지(줄기), 잎, 순, 꽃 및 강냉이 수염을 사용하는 경우(한국공개특허 특2000-36534호) 등이 공개된 바 있으나 그 작용 원리가 명확하지 않으며 효능이 충분히 검증되지 않은 실정이다.Many attempts have been made to promote hair growth by applying or taking herbal medicines to the scalp, using orchid plant extracts (Korean Patent No. 0157667), and using wormwood and mandrel (Korean Patent No. 0161338). ), In the case of using Manbyeongcho extract as an active ingredient (Korean Patent Publication No. 91-106), hair growth promoter using pine leaf extract (Korean Patent Publication No. 96-40346), hair growth promoter using silkworms (Korea Patent Publication) No. 90-2757), Ogalpi Root, Danner Ginseng Root, Red Sewage Root, Fanzama, and Hair Growth Hair Loss Agent with Buckwheat (Korean Patent Application Laid-Open No. 2000-24499), Half, Clove, Bokbunja, Sancho, Manza, Dansam And when using white porcelain (Korean Patent No. 259037), when using oil obtained by heating Wonjam, latent species, latent fetuses, silkworms, and pupa at about 200 ° C. for about 15 minutes. Heo No. 90-2757), Ginseng, Astragalus, Angelica, Shouo, Hodo, Bokbunja, Raw Yellow Sulfur, Bogolji, Songchae, Dansam, Safflower, Yeosil Chamber Mixed Extract (Korean Patent No. 90-13934) (Silkworm moth), latent species (silkworm seed), pupa (silkworm), black sesame, kelp, sesame, and walnut eggs when used under high pressure and high temperature extraction (Korean Patent Publication No. 90-5952), mung bean flour, soybean flour, Black powder, perilla powder, sesame powder, walnut powder, laver powder, mussel powder, oyster powder, anchovy powder, seaweed powder, kelp powder, yeast concentrate or its dry powder mixture (Korean Patent No. 0260673), casualties, pine needles In the case of using, and Wonjam (Korean Patent Publication No. 90-002757), When using Goji berries, roots, branches (stems), leaves, shoots, flowers, and horseradish beard (Korean Patent Publication No. 2000-36534) The back has been disclosed, but the principle of operation is not clear and the efficacy has not been fully verified.
상기와 같이, 전술한 공지의 방법 및 발모제들은 탈모 환자에게 경제적 부담 및 고통을 주거나 부작용을 유발하고, 효과가 일시적이거나 또는 단편적인 약리학적 기작 만을 사용하는 등의 문제점을 가지고 있어서, 효과가 보다 탁월하고 지속적이며, 부작용이 없는 약제들의 요구가 증대되고 있는 실정이다.As described above, the above-mentioned known methods and hair regrowth agents have problems such as economic burdens and pains to hair loss patients or cause side effects, use only temporary or fragmentary pharmacological mechanisms, and the effect is more excellent. And persistent, there is an increasing demand for drugs that do not have side effects.
한편, 디히드로테스토스테론은 또한 모근에 부착되어 있는 피지선(sebaceous gland)을 점차 커지게 하며 피지(sebum)의 분비를 촉진하는 기능을 가지고 있다.On the other hand, dihydrotestosterone also has a function of gradually increasing the sebaceous gland attached to the hair roots and promoting sebum secretion.
피지의 분비가 많아 피부가 번들거리는 증상을 흔히 지루성 피부 증상이라고 하는데 탈모 증상과 동반되는 경우가 흔하다. 지루성 피부 증상은 또한 각질이 잘 일어나게 하여 비듬이 많이 생기게 하는 등 외관상 보기 싫을 뿐 아니라 심한 경우 만성 피부 질환인 지루성 피부염으로 진행될 수 있다. 지루성 피부염은 두피, 얼굴, 귀, 가슴 등 피지의 분비가 많은 부위에 잘 생기는 만성적 염증성 질환으로 붉은 각질이 일어나며 주로 20~40 대에 많고 증상의 차이는 있겠지만 성인의 3% 정도가 발생할 정도로 흔하다. 여드름 또한 지루성 피부와 관련이 매우 높은데 피지의 분비가 많아지고 각질의 생성으로 모낭 입구가 좁아지거나 막히는 경우 잘 생기는 것으로 알려져 있다.The sebum secretion due to high sebum secretion is often referred to as seborrheic skin, which is often accompanied by hair loss. Seborrheic skin symptoms can also lead to seborrheic dermatitis, which is not desirable in appearance, such as causing keratin to occur and causing dandruff. Seborrheic dermatitis is a chronic inflammatory disease that occurs on the secretion of sebum, such as the scalp, face, ears, and chest. Red keratin occurs mainly in the 20s and 40s, and the symptoms may vary, but about 3% of adults occur. Acne is also highly associated with seborrheic skin, which is known to occur when the secretion of sebum increases and hair follicles become narrowed or blocked due to the formation of keratin.
본 발명에서 사용한 조성물의 주성분인 다래 (Actinidia arguta)는 다래나무과(Actinidiaceae)에 속하며 시베리아, 중국 북부, 한국이 원산지이다. 이와 유사한 종으로는 30종 이상이 보고되어 있고, 그 중 대표적인 것은 취다래 (A. kolomikta), 개다래 (A. polygama), 섬다래(A. rupa) 등이 있으며, 일반적으로 키위로 알려진 참다래(A. chinensisorA. deliciosa) 역시 다래나무과에 속하는 식물이다. 다래는 미후도라는 한약재로 사용되는데, 다래나무 및 동속 근연식물의 과실을 포함하고, 성질이 차고 독성이 없으며 간장질환과 위장질환의 치료 또는 비뇨기결석 치료에 처방되어 왔다(신동의약보감-전통동양약물데이타베이스, 서울대학교 천연물과학연구소, 동방미디어주식회사, 1999). Actinidia arguta , the main component of the composition used in the present invention, belongs to Actinidiaceae and is native to Siberia, northern China, and Korea. More than 30 species of similar species have been reported, and the representative ones of which are A. kolomikta , A. polygama , A. rupa , etc., commonly known as kiwi ( A. chinensis or A. deliciosa ) It is used as a Chinese herbal medicine called Mifudo. It contains the fruit of the plant of perilla and related plant, which is cold and nontoxic and has been prescribed for the treatment of liver and gastrointestinal diseases or urinary stones. Drug Database, Institute of Natural Products, Seoul National University, Dongbang Media Co., 1999).
한국특허등록 제344147호에서는 다래수액을 주재로 한 건강음료 및 그 제조방법에 관해 개시하고 있고, 한국특허등록 제134024호에서는 참다래를 주재로 한건강음료 및 그 제조방법에 관해 개시하고 있으며, 국내특허출원 제1996-10396호에서는 목화 다래 추출물 및 그의 간기능 보호제, 항암제로서의 용도에 관해 개시하고 있으며, 국내특허출원 제 2001-17524호에서는 다래 및 여러 생약추출물을 함유한 간기능회복을 위한 음료 및 그 제조방법에 대하여 개시한다. 그러나 지금까지 다래의 발모 촉진 및 지루성 피부 개선 효과에 대해서는 보고된 바가 없다.Korean Patent Registration No. 344147 discloses a health beverage mainly based on Tadasu sap and a manufacturing method thereof, and Korean Patent Registration No. 134024 discloses a Health Beverage mainly based on a Tadasu Tadala and a manufacturing method thereof. Patent Application No. 1996-10396 discloses cotton wormwood extract, its liver function protector, and its use as an anticancer agent. Domestic Patent Application No. 2001-17524 discloses beverages for liver function recovery containing wormwood and various herbal extracts. The manufacturing method is disclosed. However, there has been no report on the effects of promoting hair growth and improving seborrheic skin.
따라서 본 발명에서는 다래추출물의 발모촉진 및 지루성 피부 증상 개선 효과를 확인하기 위해, 마우스를 대상으로 하여 디히드로테스토스테론 생성 억제 및 발모 촉진에 관한 생체 실험 및 인체를 대상으로 하여 지루성 피부 증상 개선에 관한 인체시험을 실시한 결과, 본 발명에 따른 다래추출물이 디히드로테스토스테론의 혈청 내 수치를 낮춤으로써 탈모를 억제하며 지루성 피부 증상을 개선한다는 사실을 확인하여 본 발명을 완성하였다.Therefore, in the present invention, in order to confirm the hair growth and seborrheic skin symptom improvement effect of the extract, the human body to improve the seborrheic skin symptoms in vivo experiments on the inhibition of dehydrotestosterone production and the promotion of hair growth in the mouse As a result of the test, the present invention was completed by confirming that the worm extract according to the present invention suppresses hair loss and improves seborrheic skin symptoms by lowering the serum level of dihydrotestosterone.
본 발명의 목적은 생약을 주재로 하여 부작용이 없으면서도 효과가 우수한 생약 성분을 함유하는 탈모증 및 지루성 피부 증상의 예방 및 개선에 유용한 건강기능식품을 제공하는 것이다.It is an object of the present invention to provide a health functional food useful for the prevention and amelioration of alopecia and seborrheic skin symptoms, containing herbal ingredients with excellent effects, with no side effects predominantly as herbal drugs.
도 1 은 다래 실리카겔 분획물의 TLC 사진으로, 도 1a는 추출물 및 분획물들의 TLC 결과 사진이고, 도 1b는 실리카겔 분획 1의 2D-TLC 분석결과사진이고, 도 1c는 실리카겔 분획 2의 2D-TLC 분석결과사진이며,1 is a TLC picture of the silica gel fraction, Figure 1a is a TLC result of the extract and fractions, Figure 1b is a 2D-TLC analysis picture of silica gel fraction 1, Figure 1c is a 2D-TLC analysis of silica gel fraction 2 It is a photograph,
도 2 는 다래 추출물에 의한 혈청 디히드로테스토스테론 농도가 억제된 결과를 나타낸 도이고,Figure 2 is a diagram showing the result of suppressing serum dehydrotestosterone concentration by the extract of Darae,
도 3 은 다래 열수 추출물의 비극성 용매 분획에 의한 혈청 디히드로테스토스테론 농도가 억제된 결과를 나타낸 도이고,3 is a diagram showing the results of suppressing the serum dihydrotestosterone concentration by the non-polar solvent fraction of the Darae hot water extract,
도 4 는 다래 열수 추출물의 실리카겔 크로마토그래피 정제 분획물에 의한 혈청 디히드로테스토스테론 농도가 억제된 결과를 나타낸 도이고,Figure 4 is a diagram showing the results of suppressing serum dihydrotestosterone concentration by silica gel chromatography purified fractions of Darae hot water extract,
도 5 는 마우스 모델의 실험에서 생약조성물을 처리하여 유발된 모근 형성 촉진 효과에 의해 마우스 등에 털이 자라난 것을 찍은 사진으로, 도 5a는 음용수를 2주간 경구투여한 후, 마우스 등에 털이 자란 모습을 찍은 사진이고, 도 5b는 다래조추출물을 2주간 경구투여한 후, 털이 자란 모습을 찍은 사진이다.FIG. 5 is a photograph showing hair growth on a mouse and the like due to a hair root formation promoting effect induced by treating a herbal composition in a mouse model experiment. FIG. 5A shows hair growth on a mouse and the like after oral administration of drinking water for 2 weeks. It is a photograph, Figure 5b is a photograph taken after the oral administration of the seaweed extract, hair growth.
상기 목적을 달성하기 위하여, 본 발명은 다래(Actinidia arguta) 조추출물 또는 비극성용매 가용추출물 및 식품학적으로 첨가 가능한 식품보조첨가제를 포함하는 탈모 예방 및 발모 개선용 건강 기능 식품을 제공한다.In order to achieve the above object, the present invention provides a functional food for preventing hair loss and improving hair growth, including a crude extract of Actinidia arguta or a non-polar solvent soluble extract and food supplements.
또한, 본 발명은 다래 조추출물 또는 비극성용매 가용추출물 및 식품학적으로 첨가 가능한 식품보조첨가제를 포함하는 지루성 피부 질환의 예방 및 개선용 건강 기능 식품을 제공한다.The present invention also provides a health functional food for preventing and improving seborrheic skin diseases, including a crude extract or a non-polar solvent soluble extract and a food supplement.
상기 다래는 다래나무의 열매, 줄기, 줄기덩굴, 잎 및 뿌리로 이루어진 군으로 부터 하나이상 선택된 것을 포함한다.The stalks include at least one selected from the group consisting of fruits, stems, stem vines, leaves and roots.
상기 다래 조추출물은 물, 에탄올, 메탄올, 부탄올과 같은 저급 알콜 및 이들의 혼합용매, 바람직하게는 물 또는 물:에탄올 혼합용매에 가용한 추출물을 포함한다.The crude crude extract includes water, lower alcohols such as ethanol, methanol, butanol and extracts soluble in a mixed solvent thereof, preferably in a water or water: ethanol mixed solvent.
상기 다래 비극성용매 가용추출물은 클로로포름, 에틸아세테이트, 헥산, 디클로로메탄 및 에테르 등과 같은 유기용매, 바람직하게는 에틸아세테이트에 가용한 추출물을 포함한다.The above-mentioned nonpolar solvent soluble extract includes extracts soluble in organic solvents, preferably ethyl acetate, such as chloroform, ethyl acetate, hexane, dichloromethane and ether.
본 발명의 다래 추출물의 양은 전체 조성물의 0.01 내지 95 %, 바람직하게는 1 내지 80 % 중량비를 갖는 건강기능식품을 제공한다.The amount of the stalk extract of the present invention provides a dietary supplement having a weight ratio of 0.01 to 95%, preferably 1 to 80% of the total composition.
상기 건강 기능 식품은 건강을 위한 건강식품, 건강음료 등을 포함할 수 있으며, 분말, 과립, 정제, 캡슐 또는 음료 형태 등으로서 가능하다.The health functional food may include a health food for health, a health beverage, and the like, and may be in the form of powder, granules, tablets, capsules or beverages.
본 발명의 다래 추출물을 분리하는 방법은 하기와 같으며, 이하 본 발명을 상세히 설명한다.The method of separating the wormwood extract of the present invention is as follows, the present invention will be described in detail below.
본 발명의 탈모 예방, 발모 개선, 지루성 피부질환의 예방 및 개선을 위한 다래 추출물은 물 또는 알콜성 수용액으로 추출하는 것을 특징으로 하는데, 좀 더구체적으로 설명하면,Hair extract of the present invention for preventing hair loss, improving hair growth, preventing and improving seborrheic skin disease is characterized in that the extraction with water or alcoholic aqueous solution, more specifically,
본 발명의 다래 추출물은 다래를 건조시켜 분쇄화 한 후, 다래 건조 중량의 약 5 내지 25배, 바람직하게는 약 10배에 달하는 부피의 물, 메탄올, 에탄올 및 부탄올과 같은 저급 알콜 또는 이들의 약 1:0.1 내지 1:10의 혼합비를 갖는 혼합용매, 바람직하게는 물로, 20 내지 100℃, 바람직하게는 60 내지 100℃의 추출 온도에서, 약 0.5시간 내지 2일, 바람직하게는 1 시간 내지 1일 동안 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 추출방법으로 1회 내지 5회, 바람직하게는 2회 내지 3회 연속 추출하여 수득한 후, 여지로 여과하고 여액을 회전진공농축기로 20 내지 100℃, 바람직하게는 50 내지 70℃에서 감압농축한 후, 잔사를 진공동결건조또는 열풍건조 또는 분사방식에 의한 건조법 등을 통하여 물, 저급알콜 또는 이들의 혼합용매에 가용한 다래 추출물을 얻을 수 있으며, 수득된 다래 추출물은 -20℃에서 보관하면서 실험에 이용한다. 또한, 다래 추출물의 건조 분말은 증류수에 일정농도로 용해하여 사용한다.The extract of the present invention is dried and pulverized after drying, and then the volume of water, lower alcohols such as methanol, ethanol and butanol, or a drug thereof, in a volume of about 5 to 25 times, preferably about 10 times, the weight of the sputum dry weight. Mixed solvent having a mixing ratio of 1: 0.1 to 1:10, preferably with water, at an extraction temperature of 20 to 100 ° C, preferably 60 to 100 ° C, about 0.5 to 2 days, preferably 1 to 1 After extracting by extraction method such as hot water extraction, cold needle extraction, reflux cooling extraction or ultrasonic extraction for 1 to 5 times, preferably 2 to 3 times consecutively during the day, filtered through a filtrate and the filtrate to a rotary vacuum concentrator After concentration under reduced pressure at 20 to 100 ° C, preferably 50 to 70 ° C, the residue was extracted by smelting of water, lower alcohol, or a mixed solvent thereof through vacuum freeze drying, hot air drying or a drying method by spraying. Can be obtained, the obtained extract of Actinidia is used in the experiments was stored at -20 ℃. In addition, the dry powder of the stalk extract is used by dissolving to a certain concentration in distilled water.
또한 본 발명의 상기 추출물을 물에 현탁한 후, 이를 현탁액의 약 1 내지 100배, 바람직하게는 약 1 내지 5배 부피의 에틸아세테이트, 클로로포름 또는 헥산과 같은 비극성 용매를 가하여 1회 내지 10회, 바람직하게는 2회 내지 5회 분액깔때기로 분획하여 수득할 수 있다. 또한 추가로 통상의 분획 공정을 수행할 수도 있다(Harborne J.B. Phytochemical methods:A guide to modern techniques of plant analysis. 3rd Ed. pp6-7, 1998).In addition, after the extract of the present invention is suspended in water, it is added 1 to 10 times by adding a nonpolar solvent such as ethyl acetate, chloroform or hexane in a volume of about 1 to 100 times, preferably about 1 to 5 times the suspension, Preferably it can be obtained by fractionation with 2 to 5 separatory funnel. It is also possible to further carry out conventional fractionation processes (Harborne JB Phytochemical methods: A guide to modern techniques of plant analysis . 3rd Ed. Pp 6-7, 1998).
상기 본 발명의 다래 추출물은 상기 비극성용매 가용추출물을 가지고 실리카겔 컬럼크로마토그래피와 같은 흡착크로마토그래피 또는 TLC를 수행하며, 바람직하게는 실리카겔컬럼에 클로로포름:메탄올: 물의 혼합용매 100:10:1(w:w:w) 내지 20:10:0.5 비를 갖는 전개용매를 컬럼에 전개시켜 분획 후 수득할 수 있다.The Darae extract of the present invention is subjected to adsorption chromatography or TLC, such as silica gel column chromatography with the non-polar solvent soluble extract, preferably a mixed solvent of chloroform: methanol: water in a silica gel column 100: 10: 1 (w: A developing solvent having a ratio w: w) to 20: 10: 0.5 can be obtained after fractionation by developing on a column.
상기 제조방법으로 수득된 다래 조추출물, 비극성용매 가용추출물 및 컬럼크로마토그래피 분획물은 마우스에 경구투여시 혈중 디히드로테스토스테론 농도를 억제시키고, 또한 마우스 발모 모델에 다래 추출물을 경구투여시 마우스의 모근 형성 촉진을 통하여 발모를 촉진시킴을 확인하였다.Crude crude extract, non-polar solvent soluble extract and column chromatography fraction obtained by the above method inhibit blood dihydrotestosterone concentration when orally administered to mice, and also promote hair follicle formation in mice by orally administering the extract of Tara to mouse hair growth model It was confirmed to promote hair growth through.
또한 상기 다래 조추출물은 지루성 피부를 가진 환자에게 경구 투여되었을때 피부의 번들거림과 각질 증상이 개선되었다.In addition, the crude extract was improved oral and keratin symptoms of the skin when orally administered to patients with seborrheic skin.
또한 본 발명은 다래를 분쇄하고 물, 메탄올 또는 에탄올과 같은 극성 용매로 추출한 후에 감압농축하여 극성용매에 가용한 조추출물을 얻는 제 1단계;In addition, the present invention is a first step of obtaining a crude extract soluble in a polar solvent by pulverizing and extracting with a polar solvent such as water, methanol or ethanol and concentrated under reduced pressure;
상기의 조추출물을 에틸아세테이트와 같은 비극성 용매로 녹여 현탁시킨 후, 여과하여 비극성용매 가용추출물층을 분리하고 농축하여 비극성용매에 가용한 비극성 용매 가용 추출물을 얻는 제 2단계;A second step of dissolving the crude extract in a nonpolar solvent such as ethyl acetate and suspending the mixture, followed by filtration to separate the nonpolar solvent soluble extract layer and concentrate to obtain a nonpolar solvent soluble extract available in the nonpolar solvent;
이어서 2단계의 비극성용매 가용추출물을 컬럼 크로마토그래피를 수행하는데, 상기 실리카겔 컬럼에 클로로포름:메탄올: 물의 혼합용매 100:10:1(w:w:w) 내지 20:10:0.5 비를 갖는 전개용매를 컬럼에 전개시켜 분획 후, 건조하여 정제된 형태의 정제 분획물을 수득하는 제 3단계의 제조공정을 포함하는 제조방법으로 수득된 다래의 정제 분획물 (도 1a 내지 1c 참고) 및 식품학적으로 첨가 가능한 식품보조첨가제를 함유하는 탈모 방지, 발모개선 또는 지루성 피부질환 개선을 위한 건강기능식품을 제공한다.Subsequently, column chromatography of the non-polar solvent soluble extract of two stages is carried out, and a developing solvent having a chloroform: methanol: water mixed solvent of 100: 10: 1 (w: w: w) to 20: 10: 0.5 ratio in the silica gel column Is purified on a column, and then dried, to obtain purified fractions, which are obtained by a manufacturing method comprising a third step of producing a purified fraction (see FIGS. 1A to 1C) and food additives. It provides a health functional food containing food supplements to prevent hair loss, improve hair growth or improve seborrheic skin diseases.
본 발명의 상기 생약 추출물 또는 정제분획물은 탈모 예방 및 발모 개선 또는 지루성 피부질환의 개선 등의 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출물 또는 정제분획물의 양은 일반적으로 전체 식품 중량의 0.01 내지 95 중량 %, 바람직하게는 1 내지 80 중량 %로 가할 수 있으며, 건강 기능성 음료 조성물은 100㎖를 기준으로 1~30g, 바람직하게는 3 ~ 10g의 비율로 가할 수 있다.The herbal extract or tablet fraction of the present invention may be added to food or beverage for the purpose of preventing hair loss and improving hair growth or improving seborrheic skin disease. At this time, the amount of the extract or tablet fraction in the food or beverage may generally be added at 0.01 to 95% by weight, preferably 1 to 80% by weight of the total food weight, the health functional beverage composition is based on 1 100ml It can be added in the ratio of -30 g, Preferably it is 3-10 g.
건강식품용 개발을 위하여 본 발명의 상기 추출물 또는 정제분획물을 첨가할 수 있는 식품으로는, 예를 들어 각종 식품류, 음료류, 껌류, 비타민 복합제, 건강보조식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료 등의 형태로 사용할 수 있다.Foods to which the extract or tablet fraction of the present invention may be added for development for health foods include, for example, various foods, beverages, gums, vitamin complexes, health supplements, and the like, powders, granules, tablets, and capsules. Or in the form of a beverage or the like.
본 발명의 건강 기능 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물 또는 정제분획물을 함유하는 외에는 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 크실리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의비율은 본 발명의 조성물 100㎖당 일반적으로 약 1~20g, 바람직하게는 약 5~12g이다.The health functional beverage composition of the present invention has no special limitation except for containing the extract or the purified fraction as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients such as ordinary drinks. Can be. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
또한, 본 발명은 다래 추출물 0.01 내지 20중량%,아미노산류 0.001 내지 5 중량 %, 비타민류는 0.001 내지 2 중량 %, 당류 0.001 내지 20 중량 %, 유기산류 0.001 내지 10 중량 %, 적당량의 감미제 및 향료 등을 첨가한 탈모 예방 및 발모 개선 또는 지루성 피부질환의 개선을 위한 건강음료 조성물을 제공한다.The invention also Actinidia extract 0.01 to 20% by weight, amino acids 0.001 to 5% by weight, vitamins 0.001 to 2% by weight, sugars 0.001 to 20% by weight, organic acids 0.001 to 10% by weight, sweetener and flavors of proper amount Provided is a healthy beverage composition for preventing hair loss, improving hair growth, or improving seborrheic skin disease by adding such.
상기 외에 본 발명의 조성물은 여러가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
이하, 본 발명을 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 한정되는 것은 아니다.However, the following Examples and Experimental Examples are only illustrative of the present invention, and the content of the present invention is not limited to the following Examples and Experimental Examples.
실시예 1. 다래추출물의 제조Example 1. Preparation of Thigh Extract
(1-1) 물 용매를 이용한 열수추출법(1-1) Hot Water Extraction Method Using Water Solvent
경동시장의 한약재상에서 건조된 다래(미후도,Actinidia arguta)를 구입하여 실험에 사용하였다. 분쇄한 상태의 다래를 100 g을 1 리터의 증류수에 가하여 잘 교반한 다음 90 내지 95℃를 유지하는 추출온도에서 3시간 동안 환류 추출한 후 여액을 분리하였고 55~65℃로 생약추출물을 감압농축한 후, 동결건조시켜 생약조성물 분말 엑스 15.6g을 얻었다.Dried dairae (Mifudo, Actinidia arguta ) was purchased from Chinese herbal medicine in Kyungdong market and used for experiment. 100 g of pulverized bran was added to 1 liter of distilled water, and the mixture was stirred well. The mixture was refluxed for 3 hours at an extraction temperature of 90 to 95 ° C., the filtrate was separated, and the herbal extract was concentrated under reduced pressure at 55 to 65 ° C. After lyophilization, x 15.6 g of herbal composition powder was obtained.
(1-2) 물-알콜 혼합용매를 이용한 열수추출법(1-2) Hot Water Extraction Method Using Water-Alcohol Mixed Solvent
상기 실시예 1-1과 같이 분쇄된 다래 100 g에 1 리터의 25% 에탄올을 가해 잘 교반한 다음, 열을 가해 80 내지 90℃를 유지하는 추출온도에서 3시간 동안 환류 추출한 후 여액을 분리하였고 55~65℃에서 생약추출물을 감압농축한 후, 동결건조시켜 생약조성물 분말 엑스 13.5 g을 얻었다.1 g of 25% ethanol was added to 100 g of the pulverized sieve as in Example 1-1, followed by stirring. Then, the mixture was heated to reflux for 3 hours at an extraction temperature of 80 to 90 ° C., and the filtrate was separated. The herbal extracts were concentrated under reduced pressure at 55-65 ° C., and then lyophilized to obtain 13.5 g of the herbal composition powder.
실시예 2. 다래의 극성용매 및 비극성용매 가용 추출물의 제조Example 2 Preparation of Soluble Extract of Polar and Non-Polar Solvents
상기 실시예에서 제조된 열수추출물을 유기 용매를 이용하여 분획하였다.The hot water extract prepared in Example was fractionated using an organic solvent.
(2-1) 클로로포름 가용성 분획 분리(2-1) Chloroform Soluble Fraction Separation
상기 실시예 1의 다래 조추출물 5g을 50 ㎖의 증류수에 녹인 후에 클로로포름 50 ㎖와 함께 분별 깔때기(separatory funnel)에 넣어서 강하게 섞은 후에 클로로포름 불용성층(수층)과 클로로포름 가용성층을 분리하였다. 다시 클로로포름 불용성층(수층)에 클로로포름 50 ㎖을 가한 후, 혼합하고 분획하여 클로로포름 불용성 분획 및 가용성 분획을 수집하였다.5 g of the crude crude extract of Example 1 was dissolved in 50 ml of distilled water, and then mixed with 50 ml of chloroform into a separatory funnel, followed by vigorous mixing to separate the chloroform insoluble layer (aqueous layer) and the chloroform soluble layer. Again, 50 ml of chloroform was added to the chloroform insoluble layer (aqueous layer), followed by mixing and fractionation to collect a chloroform insoluble fraction and a soluble fraction.
(2-2) 에틸아세테이트 가용성 분획 분리(2-2) Separation of ethyl acetate soluble fraction
상기 클로로포름 불용성 분획(수층)에 에틸아세테이트 50 ㎖을 가하여 섞은 후에 에틸아세테이트 가용성 분획 및 불용성 분획을 분리하고, 추가로 에틸아세테이트 불용성 분획(수층)에 에틸아세테이트 50 ㎖을 넣어서 혼합 후, 분획하여 에틸아세테이트 가용성 분획 및 불용성 분획(수층)을 수집하였다.50 ml of ethyl acetate was added to the chloroform insoluble fraction (aqueous layer), followed by mixing. The ethyl acetate soluble fraction and the insoluble fraction were separated, and 50 ml of ethyl acetate was added to the ethyl acetate insoluble fraction (aqueous layer). Soluble fraction and insoluble fraction (aqueous layer) were collected.
상기 클로로포름 가용성 분획, 에틸아세테이트 가용성 분획 및 남은 수층을 감압 농축한 후에 동결건조하여 클로로포름 분획 0.34 g, 에틸아세테이트 분획 0.05 g, 물 분획 4.61 g을 얻어 시료로 사용하였다.The chloroform soluble fraction, ethyl acetate soluble fraction and the remaining aqueous layer were concentrated under reduced pressure, and then lyophilized to obtain 0.34 g of chloroform fraction, 0.05 g of ethyl acetate fraction, and 4.61 g of water fraction.
실시예 3. 실리카겔 컬럼 크로마토그래피를 이용한 다래 추출물 분획Example 3 Botanical Extract Fractions by Silica Gel Column Chromatography
상기 실시예 2-2의 에틸아세테이트 가용추출물 실리카겔 컬럼 크로마토그래피(Daisogel IR-60-W-40:63 mm)를 수행하였는데, 전개용매로는 클로로포름:메탄올:물 혼합용매 ([1]90:11:1, [2]60:10:1, [3]60:20:2) 및 메탄올[4]을 사용하였고, 시간당 300㎖로 수행하여 4 개 추가 분획물을 얻었다.The ethyl acetate soluble extract silica gel column chromatography (Daisogel IR-60-W-40: 63 mm) of Example 2-2 was carried out, and the developing solvent was a chloroform: methanol: water mixed solvent ([1] 90:11). : 1, [2] 60: 10: 1, [3] 60: 20: 2) and methanol [4] were used, which was carried out at 300 mL per hour to obtain 4 additional fractions.
2,784 mg의 에틸아세테이트 분획으로부터 얻어진 각 분획은 [1] 2,381 mg, [2] 135 mg, [3] 148 mg, [4] 98 mg 이었다.Each fraction obtained from 2,784 mg of ethyl acetate fraction was [1] 2,381 mg, [2] 135 mg, [3] 148 mg, [4] 98 mg.
상기 다래 열수추출물, 에틸아세테이트 가용추출물 및 각 분획물을 사용하여 TLC(TLC plate: Merck사, 전개용매 : 클로로포름:메탄올:물 = 9:5:1)를 실시하였다(도 1a 참조). 도 1a에서 레인 1은 다래 열수 추출물이고, 레인 2는 다래 에틸아세테이트 분획이고, 레인 3은 다래 추출물 실리카겔 분획[4], 레인 4는 다래 추출물 실리카겔 분획[3], 레인 5 는 다래 추출물 실리카겔 분획[2], 레인 6은 다래 추출물 실리카겔 분획[1] 이다.TLC (TLC plate: Merck, developing solvent: chloroform: methanol: water = 9: 5: 1) was performed using the above-mentioned hot water extract, ethyl acetate soluble extract and each fraction (see FIG. 1A). In Fig. 1a, lane 1 is a stratum hydrothermal extract, lane 2 is a stratum ethyl acetate fraction, lane 3 is a stratum extract silica gel fraction [4], lane 4 is a stratum extract silica gel fraction [3], lane 5 is a stratum extract silica gel fraction [ 2], lane 6 is the Tsu extract silica gel fraction [1].
그리고, 실리카겔 분획 [1] 및 [2]에 대하여 2D-TLC를 실시하였으며. 1차 전개용매로는 클로로포름:메탄올:물 = 9:5:1, 2차 전개용매로는 클로로포름:아세톤:물=3:8:0.5를 사용하여 실시하였다(도 1b 및 1c 참조).In addition, 2D-TLC was performed on silica gel fractions [1] and [2]. As the first developing solvent, chloroform: methanol: water = 9: 5: 1 and the second developing solvent were performed using chloroform: acetone: water = 3: 8: 0.5 (see FIGS. 1B and 1C).
실험예 1. 다래 추출물에 의한 혈중 디히드로테스토스테론의 억제 실험Experimental Example 1. Inhibition test of blood dehydrotestosterone by the extract
상기 실시예 (1-1) 및 (1-2)에서 얻은 다래의 물 추출물 및 에탄올 추출물의 혈중 디히드로테스토스테론 억제 효능을 검증하기 위하여, 마우스에게 다래추출물을 복용시킨 후 혈중 디히드로테스토스테론의 농도를 측정하였다. 6 주령의 C57BL/6 수컷 마우스를 구입하여 일 주일간 환경에 적응하도록 한 후, 7 주령이 되었을 때부터 16마리를 4군으로 나누어서 3주일간 실시예 (1-1) 및 (1-2)에서 얻은 다래 추출물 각각 100㎕ (1500 ㎍/mouse/day), 대조약물로 피나스테라이드 (finasteride, 100 ㎍/mouse/day)와 음용수 100㎕를 매일 구강 투여하였다. 3주간의 구강 투여 후 마우스를 희생시켜 채취한 혈액으로부터 혈청을 분리한 후 ELISA(IBL-Hamburg GmbH)방법을 이용하여 디히드로테스토스테론의 농도를 결정하였다.In order to verify the blood dehydrotestosterone inhibitory effects of the water extract and ethanol extracts of the haejugo obtained in Examples (1-1) and (1-2), the concentration of dehydrotestosterone in the blood Measured. Six week-old C57BL / 6 male mice were purchased and allowed to acclimate to the environment for one week, and then, at the age of seven weeks, 16 animals were divided into four groups and obtained in Examples (1-1) and (1-2) for three weeks. 100 μl (1500 μg / mouse / day) of Dalai extract, respectively, oral administration of finasteride (100 μg / mouse / day) and 100 μl of drinking water were used as control. Serum was isolated from blood collected at the expense of mice after oral administration for 3 weeks, and then the concentration of dihydrotestosterone was determined using ELISA (IBL-Hamburg GmbH).
도 2의 결과에서, 다래 물추출물 및 에탄올 추출물을 마우스 한 마리 당 1500 ㎍을 매일 복용하도록 하였을 때, 혈청 디히드로테스토스테론의 농도가 최고 90 % 까지 억제됨을 확인할 수 있고 이는 피나스테라이드를 매일 마우스 한 마리당 100 ㎍을 복용하도록 했을 때 얻을 수 있는 효과와 유사함을 확인할 수 있었다.In the results of Figure 2, when the daily dose of the water extract and ethanol extract 1500 ㎍ per mouse daily, it can be seen that the concentration of serum dihydrotestosterone is suppressed up to 90%, which means that the finasteride 100 per mouse per day It was confirmed that the effect was similar to that obtained when taking ㎍.
실험예 2. 다래 비극성용매 가용추출물의 디히드로테스토스테론 억제 효능Experimental Example 2 Dehydrotestosterone Inhibitory Effect of Soluble Extract of Non-polar Solvent
상기 실험예 1과 동일하게 C57BL/6 수컷 마우스 16 마리를 준비하여 4군으로 나눈 뒤 3 주일 간 상기 실시예 2에서 준비된 유기용매 분획, 즉 클로로포름 분획, 에틸아세테이트 분획 및 물 분획을 각각 마리당 50 ㎍ 씩 매일 구강 투여한 후, 혈청 디히드로테스토스테론의 농도를 측정하였다. 대조군에는 물 100 ㎕를 투여 하였다.In the same manner as in Experiment 1, 16 C57BL / 6 male mice were prepared, divided into 4 groups, and the organic solvent fractions prepared in Example 2, that is, the chloroform fraction, the ethyl acetate fraction and the water fraction, were prepared in Example 2 for 3 weeks. After oral administration daily, the concentration of serum dihydrotestosterone was measured. 100 μl of water was administered to the control group.
ELISA 방법을 이용하여 혈청 디히드로테스토스테론의 농도를 측정한 결과(도 3 참조), 에틸아세테이트 분획을 투여한 마우스의 혈청 디히드로테스토스테론의 농도가 최고 95 % 이상 억제되었고, 물 분획을 투여한 실험 군에서도 디히드로테스토스테론의 농도가 약하게 저하되는 경향을 띠었다. 그러나 클로로포름 분획은 혈청 디히드로테스토스테론의 농도에 영향을 미치지 못하였다.As a result of measuring the concentration of serum dihydrotestosterone using the ELISA method (see FIG. 3), the concentration of serum dihydrotestosterone was suppressed by 95% or more in the mice treated with the ethyl acetate fraction, and the experimental group in which the water fraction was administered. Also, the concentration of dihydrotestosterone tended to decrease slightly. The chloroform fraction, however, did not affect serum dihydrotestosterone levels.
실험예 3. 실리카겔 컬럼 크로마토그래피 분획에 의한 디히드로테스토스테론 억제 효능Experimental Example 3. Dehydrotestosterone inhibition effect by silica gel column chromatography fractionation
상기 실험예 1과 동일하게 C57BL/6 수컷 마우스 16 마리를 준비하여 4군으로 나눈 뒤, 실시예 3에서 얻은 실리카겔 컬럼 크로마토그래피 분획[1] 내지 [4]을 30㎍ 씩 3 주간 매일 구강 투여한 후 혈청 디히드로테스토스테론의 농도를 측정하였다. 대조군에는 물 100 ㎕를 투여하였다. 도 4에서 보는 바와 같이, ELISA 방법을 이용하여 혈청 디히드로테스토스테론의 농도를 측정한 결과, 분획[1]과 분획[2]를 처리한 마우스 군에서 강한 디히드로테스토스테론 억제 효과가 나타났다.In the same manner as in Experiment 1, 16 C57BL / 6 male mice were prepared, divided into 4 groups, and the silica gel column chromatography fractions [1] to [4] obtained in Example 3 were orally administered every 3 weeks for 30 weeks. The concentration of serum dihydrotestosterone was then measured. 100 μl of water was administered to the control group. As shown in FIG. 4, the serum dihydrotestosterone concentration was measured using an ELISA method. As a result, a strong dehydrotestosterone inhibitory effect was observed in the mice treated with the fraction [1] and the fraction [2].
실험예 4. 다래 추출물에 의한 모근 형성 촉진 효과 실험Experimental Example 4. Experiment of hair root formation promoting effect by the extract
(4-1) 다래추출물의 모근 형성 촉진(4-1) Promoting Hair Root Formation of Thigh Extract
상기 실시예 1에서 얻은 다래 열수추출물에 의한 탈모증 예방 및 치료효과를 검증하기 위하여 일반적으로 많이 사용하는 마우스 발모 모델을 응용하여 모근 형성 촉진 효과를 확인하였다. 6 주령의 C57BL/6 암컷 마우스를 구입하여 일주일간 환경에 적응하도록 한 후 7 주령이 되었을 때 바리캉을 이용하여 마우스 등의 털을 제거하였다. 이때 마우스의 모근은 모두 일제히 휴식기(telogen)에 접어들어 있었기 때문에 피부는 선홍색을 띠고 있었다. 모근이 형성되고 털이 자라면 피부는 다량의 멜라닌 색소에 의해 어두운 색으로 변하게 된다. 털을 제거한 다음 날부터 10마리의 마우스를 두 개의 군으로 나누어서 다래 물 추출물 100 ㎕ (1500 ㎍/mouse/day)와 음용수 100 ㎕를 4 주간 구강 투여하였다. 휴식기(telogen)에 있는 모근을 성장기(anagen)로 전환시켜서 모근이 활성화되는 현상은 선홍색이던 피부색이 어두워지는 것을 통하여 쉽게 관찰할 수 있다. 또한 털의 성장을 직접 관찰함으로써 다래 추출물이 가지는 모발 성장 촉진 효과를 관찰하였다.In order to verify the effect of preventing and treating alopecia due to the aloe hot water extract obtained in Example 1, it was confirmed that the hair root formation promoting effect was generally applied by applying a mouse hair growth model. Six-week-old C57BL / 6 female mice were purchased and allowed to acclimate to the environment for one week. At seven weeks of age, the hairs of the mice and the like were removed using baricang. At this time, since the hair roots of the mice all entered the telogen, the skin was bright red. When hair roots are formed and hair grows, the skin becomes dark due to a large amount of melanin pigment. From the day after hair removal, 10 mice were divided into two groups, and 100 µl of water extract (1500 µg / mouse / day) and 100 µl of drinking water were orally administered for 4 weeks. The activation of hair roots by converting the hair roots in the telogen to anagen can be easily observed through darkening of the skin color that was bright red. In addition, by directly observing the growth of hair, the hair growth promoting effect of the extract was observed.
다래 열수추출물을 투여한 마우스 군에서는 2 주일이 채 되기 전에 피부색이 어두워지는 현상이 관찰되었고 이어서 발모현상이 관찰되었으나(도 5b 참조), 물을 투여한 대조군의 마우스에서는 피부색에 아무런 변화도 관찰되지 않았다(도 5a 참조). 또한 모발의 성장도 관찰되지 않았다. 4주째에는 다래 추출물을 투여한 마우스들의 등은 거의 다 털로 덥혔으나 대조군 마우스의 등은 여전히 새로운 털이 나지 않은 것이 관찰되었다. 이 실험을 통하여 다래 추출물이 마우스의 모근 형성을 촉진을 통하여 현저하게 발모를 촉진하는 사실을 확인할 수 있었다.In the group of mice treated with hot water extract, the skin color became dark before 2 weeks and then hair growth was observed (see FIG. 5B), but no change was observed in the mouse of the control group administered with water. (See FIG. 5A). Also no hair growth was observed. At 4 weeks, the backs of the mice treated with the wormwood were almost covered with fur, but the backs of the control mice were still free of new hairs. Through this experiment, it was confirmed that the Darae extract significantly promoted hair growth by promoting hair follicle formation in the mouse.
(4-2) 다래 열수 추출물 에틸아세테이트 분획의 모근 형성 촉진(4-2) Enhancement of Hair Root Formation of Ethyl Acetate Fraction from Tela Water Extract
상기 실시예 2와 같이 다래의 열수추출물을 유기용매로 추가 분획하여 얻어진 시료, 즉 클로로포름 분획, 에틸아세테이트 분획, 물 분획의 모근 형성 촉진 효능을 확인하기 위하여 실험예 4-1과 동일한 방법으로 마우스 실험을 실시하였다. 등에 털을 제거한 마우스 5 마리씩 4군으로 나누었고 물 분획, 에틸아세테이트 분획, 클로로포름 분획을 각각 100 ㎕(50 ㎍)씩 그리고 음용수 100 ㎕를 매일 4주간 투여하였다. 실험 결과 에틸아세테이트 분획을 투여한 마우스 군에서 발모가 현저하게 촉진됨을 관찰하였다. 다른 군에서는 발모 현상이 관찰되지 않았다.Mouse experiment by the same method as Experimental Example 4-1 in order to confirm the hair root formation promoting effect of the sample obtained by further fractionating the hot water extract of Darae as an organic solvent, that is, the chloroform fraction, ethyl acetate fraction, water fraction as in Example 2 Was carried out. Five mice with hair removed on the back were divided into 4 groups, and 100 μl (50 μg) of water fraction, ethyl acetate fraction, and chloroform fraction were administered and 100 μl of drinking water for 4 weeks each day. As a result, it was observed that hair growth was significantly promoted in the group of mice treated with the ethyl acetate fraction. In other groups, no hair growth was observed.
실험예 5. 다래 덩굴의 열수추출물에 의한 디히드로테스토스테론 억제 효과Experimental Example 5. Inhibitory Effect of Dihydrotestosterone on Hot Water Extract of Twigi Vine
다래의 줄기덩굴(미후등) 열수 추출물의 디히드로테스토스테론 억제 효능을 확인하기 위해서 실험예 1과 동일하게 마우스 실험을 진행하였다. 7 주령의 C57BL/6 수컷 마우스 8 마리를 두 군으로 나누어서 각각 음용수와 다래 덩굴 추출물(1500 ㎍/mouse/day) 3주간 구강 투여한 후 혈청 디히드로테스토스테론의 농도를 측정하였다. 다래 덩굴 추출물을 복용한 마우스들은 142 pg/㎖, 193 pg/㎖, 362 pg/㎖, 1625 pg/㎖의 혈청 디히드로테스토스테론의 농도를 보였다. 따라서 다래의 덩굴(미후등)에도 역시 상당한 디히드로테스토스테론 생성억제 효능이 있음을 알 수 있다.Mouse experiment was conducted in the same manner as in Experiment 1 to confirm the dehydrotestosterone inhibitory effect of the stem of the vines (Thufu, etc.) hydrothermal extract. Eight seven-week-old C57BL / 6 male mice were divided into two groups, and the drinking water and the vine extract (1500 μg / mouse / day) were orally administered for 3 weeks, respectively, and the concentration of serum dihydrotestosterone was measured. Mice taking the vinegar extract showed serum dihydrotestosterone concentrations of 142 pg / ml, 193 pg / ml, 362 pg / ml and 1625 pg / ml. Therefore, it can be seen that the vines of the future (back light) also have a significant inhibitory effect of dihydrotestosterone production.
실험예 6. 다래 열수추출물에 의한 지루성 피부 개선 효과 실험Experimental Example 6. Experimental effect on seborrheic skin by using hot water extract
평소에 지루성 피부를 가지고 있는 세 명의 자원자를 대상으로 4 주간 다래 열수추출물(1 g)을 매일 l 회 복용하도록 하고 지루성 피부의 개선 여부를 관찰하였다. 시험에 참여한 세 사람 모두 2 주간의 복용 후 두피를 포함한 피부의 번들거림과 각질이 생성되던 증상이 개선되었음을 보고하였다.Three volunteers with seborrheic skin were taken daily for 1 week for 4 weeks of thigh hot water extract (1 g) and the improvement of seborrheic skin was observed. All three participants reported improvement in the symptoms of skin swelling and keratin formation, including the scalp after two weeks of administration.
인체 시험 결과Human test results
지원자 1Applicant 1
성명: 권수경 (여, 29세, 서울시 강남구 반포주공아파트) Name : Sukyung Kwon (female, 29, Banpojugong Apartment, Gangnam-gu, Seoul)
복용전 증상: 두피의 지루화와 각질 뚜렷, 머리를 감은 직후에도 비듬이 발생하며머리를 감을 때 다량의 머리카락이 빠짐. Symptoms before taking : Scalp and keratin of the scalp, dandruff occurs immediately after washing the hair, a large amount of hair is missing when washing the hair.
복용 후: 복용 후 2주째부터 두피의 지루 증상과 각질이 뚜렷이 감소되었으며, 탈모 현상이 50% 이상 감소하였음. After taking : After 2 weeks of treatment, seborrheic symptoms and dead skin cells of scalp were clearly reduced and hair loss was reduced by more than 50%.
지원자 2Applicant 2
성명: 박경철 (남, 27세, 서울시 관악구 봉천7동 1510-2) Name : Park Kyung-chul (Male, 27, 1510-2, Bongcheon 7-dong, Gwanak-gu, Seoul)
복용전 증상: 얼굴과 머리에 지루 증상이 있어서 세수를 한 직후에도 얼굴에서 기름기가 묻어나고 머리에서 큰 비듬이 자주 떨어지곤 하였음. Symptoms before taking : Face and hair are boring, so even after washing the face, oils get on the face and big dandruff drops off the head frequently.
복용후: 얼굴을 만졌을 때 기름기가 묻어나는 것이 확실히 줄어들었음. After taking : The oil is definitely reduced when you touch your face.
지원자 3Applicant 3
성명: 어해관 (남, 29세, 서울시 강남구 대치2동 은마아파트 20동 104호) Name : Ee Haegwan (Male, 29 years old, Eunma Apartment Building 20, 104, Daechi 2-dong, Gangnam-gu, Seoul)
복용전 증상: 지루성 피부로 특히 목 위의 부분, 즉 얼굴과 두피에 지루가 심한 편이었음. 머리를 안 감으면 매우 간지럽고 또한 두피에 여드름이 난것처럼 붉은 반점들이 생겼음. 하지만 몸은 건성의 상태이었음. Pre-dose symptoms : Seborrheic skin, especially on the neck, especially on the face and scalp. If you don't wash your hair, it's very itchy and you have red spots like acne on your scalp. But the body was dry.
복용후: 복용후 2주 전후로 해서 두피에 간지러운 증상이 사라지고 자연스럽게 여드름 같은 것이 사라졌음. 복용을 중단하자 서서히 예전과 비슷한 증세가 생겼음. After taking : 2 weeks after taking it, the scalp disappeared and the acne disappeared naturally. When I stopped taking it, I began to develop symptoms similar to the old ones.
실험예 7. 독성 실험Experimental Example 7. Toxicity Test
마우스를 사용하여 다래 추출물의 반복독성 시험을 실시하였다. 암컷 Balb/c 마우스를 열 마리씩 두 군으로 나누어서 매일 150 mg/kg 체중의 용량으로 다래추출물을 4 주간 투여하였고 대조군은 물을 투여하였다. 독성의 징후는 체중의 변화, 혈액학적 분석, 조직검사를 통해서 4 주 동안 확인하였다.Mice were used to carry out repeat toxicity test of the extracts. Female Balb / c mice were divided into two groups of ten rats each day, and the dose of 150 mg / kg body weight was administered for 4 weeks, and the control group received water. Signs of toxicity were identified for 4 weeks through changes in body weight, hematological analysis, and biopsy.
실험 결과, 다래 추출물은 그 투여 가능 용량인 150㎎/㎏에서 사망 예를 전혀 관찰할 수 없었으며, 체중 증가, 사료 섭취량, 조직검사, 혈액검사 등에서 전혀 유의한 이상을 발견할 수 없어 안전한 약물임을 확인할 수 있었다.As a result of the experiment, the extract of Dalai was not observed at 150 mg / kg of the dose. I could confirm it.
(1) 체중 및 육안 관찰: 어떠한 비정상적인 체중의 변화도 관찰되지 않았음.(1) Body weight and visual observation: No abnormal weight change was observed.
(2) 혈액학 검사: WBC, 림프구(lymphocyte), 단핵구(monocyte), 호중구 (neutrophil), 호산구(eosinophil), 호염구(basophil), RBC, 헤모글로빈 (hemoglobin), 혈소판(platelet)의 수에 있어서 어떠한 이상 징후도 발견되지 않았음.(2) Hematology test: any abnormalities in the number of WBCs, lymphocytes, monocytes, neutrophils, eosinophils, basophils, RBCs, hemoglobin, platelets No signs were found.
(3) 혈청생화학 검사: 혈청을 이용한 생화학 검사 결과 AST, ALT, LDH, 빌리루빈(bilirubin), 크레아티닌(creatinine), 글루코즈(glucose), 콜레스테롤 (cholesterol), 미네랄(minerals), 알부민(albumin), BUN, 리파아제(lipase), 아밀라제(amylase)의 수치에 있어서 어떤 이상 징후도 보이지 않았음.(3) Serum biochemical test: Biochemical test using serum AST, ALT, LDH, bilirubin, creatinine, glucose, cholesterol, cholesterol, minerals, albumin, BUN Did not show any signs of abnormality in levels of lipase, amylase.
(4) 조직 검사: 신장, 비장, 간, 흉선의 조직에서 어떤 이상도 발견되지 않았음.(4) Biopsy: No abnormalities found in the tissues of the kidneys, spleen, liver and thymus.
하기에 상기 건강 기능 식품의 제제예를 설명하나 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, an example of the preparation of the health functional food will be described, but the present invention is only intended to be described in detail rather than to limit it.
제제예 1. 건강식품의 제조Formulation Example 1 Preparation of Health Food
실시예 1의 다래 추출물..................... 1000 ㎎Botanical extract of Example 1 ..................... 1000 mg
비타민 혼합물 .............................. 20 gVitamin Blend ............... 20 g
비타민 A 아세테이트......................... 70 ㎍Vitamin A Acetate ............... 70 μg
비타민 E ................................... 1 ㎎Vitamin E ......................... 1 mg
비타민 B1 .................................. 0.13 ㎎Vitamin B1 ..................................... 0.13 mg
비타민 B2 ................................. 0.15 ㎎Vitamin B2 ................................. 0.15 mg
비타민 B6 ................................. 0.5 ㎎Vitamin B6 ................................. 0.5 mg
비타민 B12 ................................. 0.2 ㎍Vitamin B12 ................................. 0.2 μg
비타민 C ................................. 10 ㎎Vitamin C ................................. 10 mg
비오틴 ................................... 10 ㎍Biotin ......................................... 10 μg
니코틴산아미드 ........................... 1.7 ㎎Nicotinic Acid Amide ......................................... 1.7 mg
엽산 ..................................... 50 ㎍Folic Acid ......................................... 50 ㎍
판토텐산 칼슘 ............................. 0.5 ㎎Calcium Pantothenate ......................................... 0.5 mg
무기질 혼합물 ............................. 적량Mineral mixture .............
황산제1철 ................................. 1.75 ㎎Ferrous Sulfate ................................. 1.75 mg
산화아연 .................................. 0.82㎎Zinc Oxide ........................ 0.82mg
탄산마그네슘 .............................. 25.3 ㎎Magnesium Carbonate ............... 25.3 mg
제1인산칼륨 ............................... 15 ㎎Potassium monophosphate ......................................... 15 mg
제2인산칼슘 ............................... 55 ㎎Dicalcium Phosphate Dioxide ..................... 55 mg
구연산칼륨 ................................ 90 ㎎Potassium citrate ..... 90 mg
탄산칼슘 .................................. 100 ㎎Calcium Carbonate ... 100 mg
염화마그네슘 .............................. 24.8 ㎎Magnesium Chloride .............. 24.8 mg
상기 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조 방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the vitamin and mineral mixture is a composition suitable for a relatively healthy food in a preferred embodiment, the composition ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method, Granules may be prepared and used to prepare health food compositions according to conventional methods.
제제예 2. 건강음료의 제조Formulation Example 2 Preparation of Health Beverage
실시예 1의 다래 추출물...................... 1000 ㎎Botanical extract of Example 1 ...................... 1000 mg
구연산...................................... 100 ㎎Citric Acid ..................... 100 mg
올리고당 ................................... 100 gOligosaccharide ......................................... 100 g
매실농축액 ................................. 2 gPlum concentrate ..................... 2 g
타우린 ..................................... 1gTaurine ..................................... 1 g
정제수를 가하여 전체 ....................... 900㎖Purified water is added.
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.After mixing the above components according to a conventional healthy beverage production method, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container sealed sterilization and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
본 발명이 제공하는 다래 조추출물, 극성용매 및 비극성용매 추출물을 함유한 조성물은 모근의 형성 및 발모를 현저히 촉진시키고, 지루성 피부질환의 증상을 개선시키고, 부작용이 없으므로 탈모 방지 및 발모 개선 또는 지루성 피부질환의 개선을 위한 안전하고 효과적인 건강 기능 식품으로 사용될 수 있다.The composition containing the crude extract, polar solvent and non-polar solvent extract provided by the present invention significantly promotes the formation and hair growth of hair roots, improves the symptoms of seborrheic skin disease, and has no side effects, thereby preventing hair loss and improving hair growth or seborrheic skin. It can be used as a safe and effective dietary supplement for the improvement of disease.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0030089A KR100521800B1 (en) | 2003-05-13 | 2003-05-13 | Health food comprising the extract of Actinidia arguta for preventing and improving baldness disorders and seborrheic skin disorders |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0030089A KR100521800B1 (en) | 2003-05-13 | 2003-05-13 | Health food comprising the extract of Actinidia arguta for preventing and improving baldness disorders and seborrheic skin disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040097716A true KR20040097716A (en) | 2004-11-18 |
KR100521800B1 KR100521800B1 (en) | 2005-10-14 |
Family
ID=37375853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-0030089A KR100521800B1 (en) | 2003-05-13 | 2003-05-13 | Health food comprising the extract of Actinidia arguta for preventing and improving baldness disorders and seborrheic skin disorders |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100521800B1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006016728A1 (en) * | 2004-08-10 | 2006-02-16 | Helixir Co., Ltd. | Composition comprising the extract of actinidia arguta for preventing and treating baldness disorders and seborrheic skin disorders |
WO2008023266A3 (en) * | 2006-05-05 | 2009-04-09 | Gmbh Omnica | Kiwi extract |
US8394426B2 (en) | 2004-08-10 | 2013-03-12 | Viromed Co., Ltd. | Composition comprising an extract of hardy kiwi for preventing or treating baldness disorders or seborrheic skin disorders |
US9730872B2 (en) | 2012-12-04 | 2017-08-15 | Bio Spectrum, Inc. | Method for improving skin conditions with veratric acid or acceptable salt thereof as an active ingredient |
KR20210050750A (en) * | 2019-10-29 | 2021-05-10 | 주식회사 디네이쳐 | Method of selective extracting natrual material with simplified extract process |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102342705B1 (en) | 2019-12-05 | 2021-12-24 | (주)푸른터 | Method of making kiwi fruit power and kiwi fruit prepared by this method |
-
2003
- 2003-05-13 KR KR10-2003-0030089A patent/KR100521800B1/en active IP Right Grant
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006016728A1 (en) * | 2004-08-10 | 2006-02-16 | Helixir Co., Ltd. | Composition comprising the extract of actinidia arguta for preventing and treating baldness disorders and seborrheic skin disorders |
US8394426B2 (en) | 2004-08-10 | 2013-03-12 | Viromed Co., Ltd. | Composition comprising an extract of hardy kiwi for preventing or treating baldness disorders or seborrheic skin disorders |
WO2008023266A3 (en) * | 2006-05-05 | 2009-04-09 | Gmbh Omnica | Kiwi extract |
US7862840B2 (en) | 2006-05-05 | 2011-01-04 | Omnica Gmbh | Kiwi extract |
US9730872B2 (en) | 2012-12-04 | 2017-08-15 | Bio Spectrum, Inc. | Method for improving skin conditions with veratric acid or acceptable salt thereof as an active ingredient |
KR20210050750A (en) * | 2019-10-29 | 2021-05-10 | 주식회사 디네이쳐 | Method of selective extracting natrual material with simplified extract process |
WO2021085986A3 (en) * | 2019-10-29 | 2021-06-24 | 주식회사 디네이쳐 | Selective extraction method for natural substance with simplified extraction process |
Also Published As
Publication number | Publication date |
---|---|
KR100521800B1 (en) | 2005-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101567129B1 (en) | Acacia macrostachya seed extract and compositions containing same | |
WO2007131677A1 (en) | Use of ginsenosides and extracts containing them | |
KR102113193B1 (en) | Composition for improving skin conditions comprising artemisiae annuae herba, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
JP5006193B2 (en) | Composition for prevention and treatment of hair loss and seborrheic skin disease comprising kiwifruit extract | |
US20130122128A1 (en) | Composition comprising an extract of hardy kiwi for preventing or treating baldness disorders or seborrheic skin disorders | |
JP2008525462A (en) | Methods and compositions for reducing the appearance of wrinkles | |
KR20130039145A (en) | Composition for preventing hair loss or promoting hair growth comprising extracts of panax ginseng and hijikia fusiforme | |
KR100521800B1 (en) | Health food comprising the extract of Actinidia arguta for preventing and improving baldness disorders and seborrheic skin disorders | |
KR20210058772A (en) | Composition for treating hair loss and promoting hair growth | |
KR101541470B1 (en) | Composition for preventing hair loss or promoting hair growth comprising Ginsenoside F2 | |
KR101705354B1 (en) | A composition comprising the alcohol extract of Botrychium ternatum for preventing or treating skin inflammation | |
US20240115642A1 (en) | Composition for preventing hair loss or promoting hair growth comprising milk thistle flower extract as an active ingredient | |
KR20140148227A (en) | Composition for preventing depilation and hair growth promotion and Method of preparing thereof | |
KR20150061839A (en) | Manufacturing method of composition of enzyme for preventing lose of hair and Composition of enzyme for preventing lose of hair manufactured by the same | |
KR20180092438A (en) | Composition for promoting hair growth and the method thereof | |
KR102244585B1 (en) | Complex cosmetic composition for improving skin-aging | |
KR101981678B1 (en) | Complex antioxidant extract and cosmetic composition for promoting hair growth and improving scalp and hair | |
JP2004155961A (en) | Antioxidant | |
KR20170025363A (en) | Composition for improving skin | |
KR20070105416A (en) | Composition for whitening comprising extracts from betula platyphylla var. japonica hara | |
KR102316334B1 (en) | Food or Cosmetic Composition For Improving Hair Health Containing Complex Natural Product Extract | |
KR102316957B1 (en) | Composition for preventing hair loss and enhancement of hair growth comprising pterosin compounds or derivative thereof | |
KR20110080998A (en) | Composition for improving wrinkle and elasticity containing black currant anthocyanins | |
KR100554948B1 (en) | Herbal composition for preventing and improving baldness | |
KR101432873B1 (en) | Composition for preventing hair loss or promoting hair growth comprising extracts of Panax ginseng and Forsythiae fructus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120928 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20130826 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140827 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150819 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20160927 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180918 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20191007 Year of fee payment: 15 |